Detalles de la búsqueda
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133584
2.
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Mod Pathol
; 35(12): 1888-1899, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115922
3.
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Mod Pathol
; 33(5): 792-801, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31740722
4.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol
; 20(3): 371-382, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30765258
5.
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Breast Cancer Res
; 21(1): 30, 2019 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30795773
6.
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
Breast Cancer Res Treat
; 176(3): 557-568, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31065870
7.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29589138
8.
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Mod Pathol
; 35(12): 2033, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36253399
9.
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Breast Cancer Res
; 18(1): 110, 2016 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27825388
10.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27372069
11.
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat
; 154(3): 543-55, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26590813
12.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast Cancer Res Treat
; 154(2): 275-86, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26493064
13.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Cancer Res Treat
; 151(2): 373-84, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25935582
14.
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Clin Cancer Res
; 29(23): 4908-4919, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733800
15.
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Lung Cancer
; 175: 141-151, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535121
16.
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
J Immunother Cancer
; 11(10)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880184
17.
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
J Thorac Oncol
; 18(9): 1233-1247, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37356802
18.
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Lung Cancer
; 174: 27-35, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36283211
19.
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Lung Cancer
; 172: 94-99, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36030612
20.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172272